Drug intelligence / Profile preview

3Z-20-004

Development stage: Preclinical
Lead developer: 3Z Pharmaceuticals
Modality: Small Molecules

Overview

3Z-20-004 is an investigational small-molecule drug being developed by 3Z Pharmaceuticals (3Z ehf) as a repurposed agent for neurological indications, primarily attention-deficit/hyperactivity disorder (ADHD) and sleep initiation and maintenance disorders.[3][5][7][9] It is part of 3Z’s pipeline of novel ADHD therapeutics identified using behavior-based zebrafish screening and is currently at the preclinical stage, with no publicly disclosed molecular target or detailed mechanism of action.[3][5][7][9] Available information indicates development within the nervous system therapeutic area, but specific pharmacology, molecular target, and clinical data have not yet been reported in the public domain.[3][9]

Other names: 3Z-20-004(ADHD)3Z-20-004(Insomnia)

Beyond the preview

Go deeper on 3Z-20-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3Z-20-004.

Explore the full profile